Phase II Trials in Journal of Clinical Oncology

被引：82

作者：

Cannistra, Stephen A. ^{[1
]}

机构：

[1] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Program Gynecol Med Oncol, Boston, MA 02215 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 19期

关键词：

DESIGN; RANDOMIZATION; CANCER;

D O I：

10.1200/JCO.2009.23.1811

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：3073 / 3076

页数：4

共 11 条

[1] Improving the quality of reporting of randomized controlled trials - The CONSORT statement [J].

Begg, C ;

Cho, M ;

Eastwood, S ;

Horton, R ;

Moher, D ;

Olkin, I ;

Pitkin, R ;

Rennie, D ;

Schulz, KF ;

Simel, D ;

Stroup, DF .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (08) :637-639

[2] The ethics of early stopping rules: Who is protecting whom? [J].

Cannistra, SA .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (09) :1542-1545

[3] Blinded independent central review of progression-free survival in phase III clinical trials: Important design element or unnecessary expense? [J].

Dodd, Lori E. ;

Korn, Edward L. ;

Freidlin, Boris ;

Jaffe, C. Carl ;

Rubinstein, Lawrence V. ;

Dancey, Janet ;

Mooney, Margaret M. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (22) :3791-3796

[4] Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer [J].

Engelman, Jeffrey A. ;

Jaenne, Pasi A. .

CLINICAL CANCER RESEARCH, 2008, 14 (10) :2895-2899

[5] Can the pharmaceutical industry reduce attrition rates? [J].

Kola, I ;

Landis, J .

NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (08) :711-715

[6] Clinical trial designs for cytostatic agents: Are new approaches needed? [J].

Korn, EL ;

Arbuck, SG ;

Pluda, JM ;

Simon, R ;

Kaplan, RS ;

Christian, MC .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (01) :265-272

[7] Optimising the design of phase II oncology trials: The importance of randomisation [J].

Ratain, Mark J. ;

Sargent, Daniel J. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :275-280

[8] Phase II placebo-controlled randomized discontinuation trial of sorafnib in patients with metastatic renal cell carcinoma [J].

Ratain, Mark J. ;

Eisen, Tim ;

Stadler, Walter M. ;

Flaherty, Keith T. ;

Kaye, Stan B. ;

Rosner, Gary L. ;

Gore, Martin ;

Desai, Apurva A. ;

Patnaik, Amita ;

Xiong, Henry Q. ;

Rowinsky, Lric ;

Abbruzzese, James L. ;

Xia, Chenghua ;

Simantov, Ronit ;

Schwartz, Brian ;

O'Dwyer, Peter J. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (16) :2505-2512

[9] Design issues of randomized phase II trials and a proposal for phase II screening trials [J].

Rubinstein, LV ;

Korn, EL ;

Freidlin, B ;

Hunsberger, S ;

Ivy, SP ;

Smith, MA .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (28) :7199-7206

[10] Clinical trial designs for predictive marker validation in cancer treatment trials [J].

Sargent, DJ ;

Conley, BA ;

Allegro, C ;

Collette, L .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (09) :2020-2027

← 1 2 →